Skip to main content
SpringerLink
Log in

Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

We investigated the ubiquitination and degradation of a tumor antigen, the HER-2/neu (HER-2) protooncogene product which is overexpressed in epithelial cancers. HER-2 degradation was investigated in the ovarian tumor line, SKOV3.A2, that constitutively overexpressed long-life HER-2. We used as agonist geldanamycin (GA), which initiated downmodulation of HER-2 from the cell surface. HER-2 was polyubiquitinated and degraded faster in the presence than in the absence of GA. GA did not decrease HLA-A2 expression. Presentation of the immunodominant cytotoxic T lymphocyte (CTL) epitope, E75 (369–377) from SKOV.A2 was inhibited by proteasome inhibitors, such as LLnL but was enhanced by cysteine protease inhibitors such as E64, indicating that both the proteasome and cysteine proteases are involved in epitope formation but have different effects. Enhanced tumor recognition was not an immediate or early effect of GA treatment, but was evident after 20 h of GA treatment. In contrast, 20 h GA treatment did not increase tumor sensitivity to LAK cell lysis. Twenty hour GA-treated SKOV3.A2 cells expressed an unstable HER-2 protein synthesized in the presence of GA, of faster electrophoretic mobility than control HER-2. This suggested that the newly synthesized HER-2 in the presence of GA was the main source of epitopes recognized by CTL. Twenty hour GA-treated SKOV3.A2 cells were better inducers of CTL activity directed to a number of HER-2 CTL epitopes, in peripheral blood mononuclear cells compared with control untreated SKOV3.A2 cells. Thus, induction of HER-2 protein instability enhanced the sensitivity of tumor for CTL lysis. Increased HER-2 CTL epitopes presentation may have implications for overcoming the poor immuno-genicity of human tumors, and design of epitope precursors for cancer vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS: Self-antigens expressed by solid tumor do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J Exp Med 186: 645–653, 1997

    Google Scholar 

  2. Onrust SV, Hartl PM, Rosen SD, Hanahan D: Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J Clin Invest 97: 54–64, 1996

    Google Scholar 

  3. O'Connell J, Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075–1082, 1996

    Google Scholar 

  4. Seung LP, Rowley DA, Dubey P, Schreiber H: Synergy between T cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci USA 92: 6254–6258, 1995

    Google Scholar 

  5. Kono K, Halapi E, Hising C, Petersson M, Gerdin E, Vanky F, Kiessling R: Mechanisms of escape from CD8+ T cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression. Int J Cancer 70: 112–119, 1997

    Google Scholar 

  6. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, Robbins P, Parmiani G, Storkus WJ, Lotze MT: Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 98: 1633–1641, 1996

    Google Scholar 

  7. Wick M, Dubey P, Doeppen H, Siegel CT, Fields PE, Chen L, Bluestone JA, Schreiber H: Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic energy. J Exp Med 186: 229–238, 1997

    Google Scholar 

  8. Michalek M, Grant EP, Gramm C, Goldberg KL, Rock KL: A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 363: 552, 1993

    Google Scholar 

  9. Cox JH, Galardy P, Bennink JR, Yewdell JW: Presentation of endogenous and exogenous antigens is not affected by inactivation of e1 ubiquitin-activating enzyme in temperature-sensitive cell lines. J Immunol 154: 511–519, 1995

    Google Scholar 

  10. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg KL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I. Cell 78: 761–771, 1994

    Google Scholar 

  11. Yewdell JW, Anton LC, Bennink JR: Defective ribosomal products (DRiPs): A major source of antigenic peptides for MHC class I molecules? J Immunol 157: 1823–1826, 1996

    Google Scholar 

  12. Pickaut CB: Targeting of substrates to the 26S proteasome. FASEB J 11: 1055–1066, 1997

    Google Scholar 

  13. Hicke L: Ubiquitin-dependent internalization and down-regulation of plasma membrane proteins. FASEB J 11: 1215–1226, 1997

    Google Scholar 

  14. Vinitsky A, Anton LC, Snyder HL, Orlowski M, Bennink JR, Yewdell JW: Generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors. Involvement of nonproteasomal cytosolic proteases in antigen processing. J Immunol 159: 554–564, 1997

    Google Scholar 

  15. Lopez D, Del Val M: Selective involvement of proteasome and cysteine proteases in MHC class I antigen presentation. J Immunol 159: 5769–5772, 1997

    Google Scholar 

  16. Craiu A, Akopian T, Goldberg A, Rock KL: Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci USA 94: 10850–10855, 1997

    Google Scholar 

  17. Kupio T, Kankaanranta A, Jalava P, Kronqvist K, Kotkansala T, Weber E, Collan Y: Cystein proteinase inhibitor cystatin A in breast cancer. Cancer Res 58: 432–436, 1998

    Google Scholar 

  18. Pasleau F, Grooteclaes M, Gol-Winkler R: Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: Measurement of c-erbB2 mRNA half-life. Oncogene 8: 849–854, 1993

    Google Scholar 

  19. Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteasomal degradation of the p185 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271: 22796–22801, 1996

    Google Scholar 

  20. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer JD, Neckers L: p185erbB2 binds to grp94 in vivo. J Biol Chem 271: 4974–4977, 1996

    Google Scholar 

  21. Hartmann F, Horak EM, Cho C, Lupu R, Bolen JB, Stetler-Stevenson A, Pfreundschuh M, Waldmann TA, Horak ID: Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced HER-2/neu activation, receptor expression and proliferation of HER-2-positive malignant cell lines. Intl J Cancer 70: 221–229, 1997

    Google Scholar 

  22. Fisk B, Blevins TL, Wharton JT, Ioannides GC: Identification of an immunodominant peptide of HER-2/neu proto-oncogene recognized by ovarian tumor specific CTL lines. J Exp Med 181: 2109–2117, 1995

    Google Scholar 

  23. Quyang X, Gulliford, Zhang H, Huang GC, Epstein R: Human cancer cells exhibit PKC-dependent c-erb-2 transmodulation that correlates with phosphatase sensitivity and kinase activity. J Biol Chem 271: 21786–21792, 1996

    Google Scholar 

  24. Ward NE, Gravitt KR, O'Brien CA: Irreversible inactivation of protein kinase C by a peptide-substrate analog. J Biol Chem 270: 8056–8060, 1995

    Google Scholar 

  25. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186: 1183–1187, 1997

    Google Scholar 

  26. Anderson BW, Peoples GE, Murray JL, Gershenson DM, Ioannides CG: Peptide priming of cytolytic activity to HER-2 epitope (369-377) in healthy individuals. Clin Cancer Res (in press)

  27. Yang B, Hahn YS, Hahn CS, Braciale TJ: The requirement for proteasome activity in class I MHC antigen presentation is dictated by the length of preprocessed antigen. J Exp Med 183: 1545–1552, 1996

    Google Scholar 

  28. Fisk B, Chesak B, Wharton JT, Ioannides CG: Sequence motifs of human HER-2 proto-oncogene important for peptide binding to HLA-A2. Int J Oncol 5: 51–63, 1994

    Google Scholar 

  29. Kundig TM, Shahinian A, Kawai K, Mittrucker HW, Sebzda E, Bachmann MF, Mak TW, Ohashi PS: Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 5: 41–52, 1996

    Google Scholar 

  30. Kundig TM, Backmann MF, Oehen S, Hoffman UW, Simard TJ, Kalberer CP, Pircher H, Ohashi PS, Hengartner H, Zikernagel RM: On the role of antigen in maintaining cytotoxic T cell memory. Proc Natl Acad Sci USA 93: 9716–9723, 1996

    Google Scholar 

  31. Cai Z, Sprent J: Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro. J Exp Med 183: 2247–2257, 1996

    Google Scholar 

  32. Ioannides CG, Fisk B, Fan D, Biddison WA, Wharton JT, O'Brien CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER2/neu proto-oncogene. Cell Immunol 150: 225–234, 1993

    Google Scholar 

  33. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R: Identification of new HER-2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163: 1037–1044, 1999

    Google Scholar 

  34. Disis ML, Smith JW, Murphy RE, Chen W, Cheever MA: In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54: 1071–1076, 1994

    Google Scholar 

  35. Goth S, Nguyen V, Shastri N: Generation of naturally processed peptide/MHC class I complexes is independent of the stability of endogenously synthesized precursors. J Immunol 157: 1894–1904, 1996

    Google Scholar 

  36. Grant EP, Michalek MT, Goldberg AL, Rock KL: Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol 155: 3750–3758, 1995

    Google Scholar 

  37. Tobery W, Siliciano RF: Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 185: 909–920, 1997

    Google Scholar 

  38. Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y: Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J 12: 961–971, 1993

    Google Scholar 

  39. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J: Determinant selection of MHC class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 180: 1471–1483, 1996

    Google Scholar 

  40. Alexander-Miller M, Leggatt GR, Sarin A, Berzofsky JA: Role of antigen, CD8, and cytotoxic T lymphocyte (CTL0 avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 184: 485–492, 1996

    Google Scholar 

  41. Houghton A: Cancer antigens: Immune recognition of self and altered self. J Exp Med 180: 35–42, 1994

    Google Scholar 

  42. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of cell costimulation. Annu Rev Immunol 14: 233–258, 1996

    Google Scholar 

  43. Suzuki I, Fink P: Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through fas ligand. J Exp Med 187: 123–128, 1998

    Google Scholar 

  44. Valitutti S, Muller S, Dessing M, Lanzavecchia A: Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183: 1917–1921, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, The University of Texas M.D., Anderson Cancer Center, Houston, TX, USA

    Agapito Castilleja, Bruce Swearingen II, Eric Swan, Andrzej P. Kudelka, David M. Gershenson & Constantin G. Ioannides

  2. Department of Cancer Biology, The University of Texas M.D., Anderson Cancer Center, Houston, TX, USA

    Nancy E. Ward & Catherine A. O'Brian

  3. Department of Bioimmunotherapy, The University of Texas M.D., Anderson Cancer Center, Houston, TX, USA

    Michal A. Gillogly & James L. Murray

Authors
  1. Agapito Castilleja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy E. Ward
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine A. O'Brian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruce Swearingen II
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Swan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michal A. Gillogly
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James L. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrzej P. Kudelka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. David M. Gershenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Constantin G. Ioannides
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castilleja, A., Ward, N.E., O'Brian, C.A. et al. Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol Cell Biochem 217, 21–33 (2001). https://doi.org/10.1023/A:1007267814251

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007267814251

Search

Navigation